头孢曲松和头孢哌酮钠舒巴坦钠治疗下呼吸道感染的成本-效果分析

目的对头孢曲松和头孢哌酮钠舒巴坦钠治疗下呼吸道感染进行药物经济学分析，为临床提供用药参考方案。方法采用统计研究和成本-效果分析方法，对下呼吸道感染治疗成本进行药物经济学评价。结果头孢曲松和头孢哌酮钠舒巴坦钠治疗下呼吸道感染总有效率分别为91．67％和94．82％，效果无显著差异（P〉0．05）；治疗成本分别为133元和396．2元，差异有显著性。结论头孢曲松治疗下呼吸道感染比头孢哌酮钠舒巴坦钠更经济，符合药物经济学原则。

Cost-Effectiveness Analysis of Ceftriaxone Sodium and Sulbactam and Cefoperazone for Treatment of Lower Respiratory Infection

Objective To investigate the potency ratio of ceftriaxone sodium and sulbactam and cefoperazone for the treatment of lower respiratory infections. Methods The statistical research and cost- effectiveness analysis were adopted to conduct the pharmacoeconomic assessment of cost for lower respiratory infection. Results The effective rates of ceftriaxone sodium and sulbactam and cefoperazone were 91.67% and 94. 82% respectively, there was no statistically significant difference （P〉0,05）. The costs of two drugs were 133 yuan and 396.2 yuan respectively, with significant difference（ P 〈 0. 05）. Conclusion The pharmacoeconomic analysis indicates that ceftriaxone sodium is superior to sulbaetam and cefoperazone for the treatment of lower respiratory infection.